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ABSTRACT 
Background: Pre-clinical and clinical studies indicate that a combination of docetaxel 
and trastuzumab may effectively treat patients with human epidermal growth factor 
receptor-2 (HER-2) overexpressing metastatic breast cancer. Therefore, this study was 
designed to compare the efficacy, safety and tolerability of trastuzumab plus docetaxel 
and docetaxel monotherapy in HER-2 Positive Metastatic Breast Cancer patients. 
Methods: A total of 40 patients were randomly assigned to two groups. Twenty patients 
(Group 1) were assigned into six cycles of docetaxel 75 mg/m2 every 21 days with 
trastuzumab 8 mg/kg loading dose followed by 6 mg/kg weekly and Group 2, twenty 
patients were assigned into six cycles of docetaxel 75 mg/m2 every 21 days.  
Results: Objective responses of Trastuzumab with docetaxel combination and 
docetaxel monotherapy were found to be similar without any significant difference 
between the study groups. Subjective responses after sixth cycle were found to be 
similar in both the groups. Side-effects were similar in both the study groups. The most 
common haematological toxicity was leukopenia. Non-Haematological toxicities 
reported were alopecia, peripheral neuropathy, myalgia/arthralgia and nail 
discolouration and they were almost equal in both the study groups. 
Conclusion: Trastuzumab with docetaxel combination was certainly a promising 
combination for metastatic breast cancer in patients with HER-2-overexpression. 
Further long term studies regarding overall survival, overall response rate and time to 
progression would be needed to confirm the effectiveness of this combination over 
docetaxel monotherapy in the metastatic setting. 
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